logo-loader
RNS
viewValiRx PLC

ValiRx PLC - Shareholder Requisition Notice

RNS Number : 0337F
ValiRx PLC
04 March 2020
 

ValiRx Plc

("ValiRx" or the "Company")

Shareholder Requisition Notice

 

London, UK, 4 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received a letter from a group of shareholders (the "Letter") who hold in excess of 5% of the issued share capital of the Company, requiring that the Company convene, as soon as reasonably practicable, a general meeting, at which resolutions will be proposed to remove George Morris and Satu Vainikka as directors of the Company.

 

The Letter is a requisition under section 303 of the Companies Act 2006.

 

The Company is mindful that, pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

 

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Kevin Alexander, Non-executive Director

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

[email protected]



Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880



Allenby Capital Limited (Joint Broker)

Jeremy Porter / Alex Brearley (Corporate Finance)

Kelly Gardiner (Equity Sales)

Tel: +44 (0) 20 3328 5656

 



ETX Capital Limited (Joint Broker)

Thomas Smith

Tel: +44 (0) 20 7392 1568

 

Novum Securities Limited (Joint Broker)

Colin Rowbury

Tel: +44 (0) 20 7399 9400

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCJIMATMTTMBFM

Quick facts: ValiRx PLC

Price: 6.75

Market: AIM
Market Cap: £2.43 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ValiRx Plc enjoying strong industry interest in its cancer treatments

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio. Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship...

on 19/7/18